Printer Friendly

BIOCHEM IMMUNOSYSTEMS INC. SIGNS STRATEGIC ALLIANCE IN JAPAN

 LAVAL, Quebec, April 1 /PRNewswire/ -- BioChem ImmunoSystems, Inc., a subsidiary of BioChem Pharma (NASDAQ: BCHXF; TSE, MSE: BCH) today announced that it has signed an exclusive distribution agreement with Nippon Shoji Kaisha Ltd. (NSK) for their retrovirology product line.
 In addition to retrovirology products (diagnostic kits), this three year agreement covers certain other products for infectious diseases, as well as sales of the Labotech(TM) analyzer.
 "We are very confident of substantially increasing BioChem ImmunoSystems' international sales and marketing networks," said Silvio Nuzzo, president and chief executive officer of BioChem ImmunoSystems Inc. Mr. Nuzzo said this agreement with one of Japan's top companies will help BioChem ImmunoSystems penetrate one of the world's most active markets.
 NSK was founded in 1920 and is one of Japan's largest pharmaceutical companies, with annual sales of $1.5 billion. It operates a research and development laboratory as well as three plants manufacturing pharmaceutical products, diagnostic reagents and medical equipment.
 BioChem ImmunoSystems is involved in the research, development, manufacturing and commercialization of reagents and automated diagnostic instruments. It has affiliates in Italy and Spain and distributors around the world.
 -0- 4/1/93
 /CONTACT: Jean-Yves Duthel of BioChem ImmunoSystems, Inc., 514-681-1744, or Fern Lazar or Kate de Santis of Dewe Rogerson, Inc., 212-688-6840/
 (BCHXF)


CO: BioChem ImmunoSystems, Inc.; Nippon Shoji Kaisha Ltd. ST: IN: MTC SU:

SH-SM -- NY017 -- 1867 04/01/93 08:59 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1993
Words:230
Previous Article:COMPANIES AGREE TO PAY PAST COSTS AT IWP SUPERFUND SITE
Next Article:NEW VALLEY CORPORATION ENTERS CHAPTER 11
Topics:


Related Articles
BIOCHEM GETS ANOTHER MAJOR SALES CONTRACT IN EUROPE
BIOCHEM IS STILL GROWING
BIOCHEM IS STILL GROWING
INFLAZYME ANNOUNCES JOINT VENTURE TODEVELOP AND MARKET A TEST FOR TUBERCULOSIS
ARES-SERONO ANNOUNCES SIGNATURE OF AGREEMENT TO SELL ITS DIAGNOSTIC DIVISION TO BIOCHEM PHARMA, INC.
Saliva Diagnostic Systems' Product Sales, Focus on Business Operations Key to Success Investors Told at Annual Meeting
BIOMERICA Signs an Agreement With BioChem ImmunoSystems
BIOCHEM PHARMA OBTAINS LICENSE ON SECOND LOOK(TM) COMPUTER-BASED BREAST CANCER DETECTION SYSTEM
Biochem Pharma announces sale of hematology operations of its diagnostics subsidiary.
IMMUCON Inc. - Innovative male fertility diagnostic test - Strategic Alliance with BIOCHEM Immunosystems.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters